Actively Recruiting
Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture
Led by Mayo Clinic · Updated on 2026-03-23
18
Participants Needed
1
Research Sites
314 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate Neostigmine and Glycopyrrolate to treat post-dural puncture headache (PDPH) to reduce the proportion of postpartum women with a PDPH requiring epidural blood patch (EBP) who developed a PDPH after accidental dural puncture.
CONDITIONS
Official Title
Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Post-dural puncture headache after documented dural puncture with a Tuohy needle during epidural analgesia for labor with no other headache explanation
- Headache onset within 72 hours after delivery
You will not qualify if you...
- Patient refusal to participate
- Pain score less than 4 on the visual analog scale
- History of migraine headaches
- Asthma
- Arrhythmia
- Heart block
- Myasthenia gravis
- Inability to understand pain scores or other questionnaires
- Inability to speak English
- Contraindication to acetaminophen or NSAIDs
- Body temperature over 38.5°C
- Prior epidural blood patch done for this headache
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here